Archives
Haloprogin: From Spectrum to Translation
2026-10-06
Haloprogin offers a useful translational case study: strong dermatophyte activity, broader yeast and selected Gram-positive coverage, and unresolved molecular targets. This evidence-led perspective separates historical findings from modern research questions and highlights the boundaries between in vitro potency, topical exposure, and clinical relevance.
Mifepristone (RU486): Reading Receptor Evidence
2026-10-06
Mifepristone (RU486) is more than a progesterone receptor antagonist: it is a tool for testing how receptor context shapes reproductive and tumor biology. This evidence-centered review connects reported anticancer and sperm-function findings with a tissue-specific nuclear-receptor study while clearly separating evidence from hypothesis.
Chloramphenicol as a Lens on Plasmid Evidence
2026-10-05
Chloramphenicol is more than a selection antibiotic: it can help frame how plasmid-associated resistance evidence is interpreted. This article connects its translation-inhibiting mechanism with the layered genomic, phenotypic, and epidemiological analysis reported by Chen et al. in carbapenem-resistant Enterobacter cloacae.
Cabozantinib: Reading Adaptive Kinase Signaling
2026-10-05
Cabozantinib and XL184 are best understood as time-dependent network perturbations rather than single-pathway inhibitors. This article interprets recent renal cell carcinoma phosphoproteomics alongside product-level pharmacology to clarify what the evidence shows, where it remains limited, and how to read adaptive signaling without overinterpreting isolated biomarkers.
SP2509 and LSD1: Reading Epigenetic Evidence
2026-10-04
SP2509 is a Lysine-specific demethylase 1 antagonist whose reported AML activity illustrates how epigenetic mechanisms should be interpreted across molecular contexts. This evidence-led analysis connects LSD1 biology with a breast cancer co-targeting study while separating biochemical selectivity, chromatin remodeling, cellular response, and translational relevance.
Doxorubicin Hydrochloride: Evidence and Context
2026-10-03
Doxorubicin hydrochloride, also known as Adriamycin HCl, is an anthracycline chemotherapeutic used in cancer biology and cardiotoxicity research. This overview distinguishes established research context from findings in a supplied 2025 mouse study examining thymoquinone protection against doxorubicin-associated cardiac injury. The study linked cardiac protection with antioxidant responses, Nrf2/HO-1 signaling, mitochondrial preservation, and reduced ferroptosis-associated markers. However, the evidence remains preclinical and mechanistically suggestive rather than clinically conclusive. Important uncertainties include whether cardioprotection preserves anticancer activity, whether biomarker changes demonstrate causal ferroptosis inhibition, and how well the findings translate across species, tumor types, treatment schedules, and patient populations.
Cross-Kingdom Promoters for E. coli and Yeast
2026-10-02
Son and colleagues developed modular hybrid promoters that combine bacterial and yeast transcriptional and translation-initiation elements for coordinated gene expression in Escherichia coli and Saccharomyces cerevisiae. The study supports a practical design framework for portable genetic constructs, while also showing that cross-host consistency must be evaluated quantitatively rather than assumed from sequence portability alone.
Dual Luciferase Reporter Gene System: K1136 Guide
2026-10-01
The Dual Luciferase Reporter Gene System uses firefly and Renilla luciferases to measure two reporter signals in one mammalian-cell sample. The K1136 format supports normalization, direct reagent addition, and gene expression regulation studies, while the cited BMSC study provides a biological hypothesis that can be tested with reporter constructs.
NF-κB/miR-202-5p/HMGB2 in Septic AKI
2026-10-01
The reference study identifies an NF-κB/miR-202-5p/HMGB2 negative feedback loop that limits renal inflammation and tubular cell death during sepsis-induced acute kidney injury. Its combined in vitro and in vivo evidence positions miR-202-5p as an inducible protective response and clarifies how HMGB2 links inflammatory signaling to kidney injury.
DFCP1 Controls Starvation-Driven ATGL Lipolysis
2026-09-30
The reference study identifies DFCP1/ZFYVE1 as a nutrient-sensitive regulator of lipid droplet catabolism that controls ATGL recruitment and retention during starvation. Its central insight is that DFCP1 can recruit ATGL to lipid droplets while restricting its dynamic release, linking protein mobility to the rate of lipolysis and providing a mechanistic framework for studying lipid mobilization under metabolic stress.
Chloramphenicol: Plasmid Selection and Gene Mobility
2026-09-30
Chloramphenicol is a precise bacterial protein synthesis inhibitor for plasmid selection assays, but its value extends beyond simple growth selection. This article explains how recent CREC transmission research can improve assay interpretation, plasmid tracking, and experimental controls.
Multiplexed CRISPR–Cas Genome Engineering
2026-09-29
This 2025 review synthesizes how multiple CRISPR–Cas guide RNAs can coordinate gene disruption, structural-variant formation, epigenetic regulation, and selective cellular stress. Its practical value lies in showing that multiplexing is not a single editing protocol but a design framework whose outcomes depend on guide arrangement, nuclease burden, repair pathways, and cellular context.
Cefodizime: Mechanism, Activity, and Research Use
2026-09-29
Cefodizime is a third-generation cephalosporin antibiotic and bacterial cell wall synthesis inhibitor with activity against selected Gram-positive and Gram-negative organisms. Its research profile includes β-lactamase stability, reported immunomodulatory effects, renal elimination, and clear limitations against Pseudomonas aeruginosa, MRSA, and many ESBL-producing strains.
FOXA1–PUS1–EIF3b Axis in Bone Metastasis
2026-09-28
The 2024 reference study identifies a non-enzymatic function of PUS1 in prostate cancer bone metastasis: PUS1 preserves EIF3b stability and thereby supports metastatic behavior. It further places PUS1 under FOXA1 transcriptional control and provides a mechanistic framework for evaluating PUS1–EIF3b signaling in metastatic prostate cancer models.
WM-8014 in SCC Resistance: Why Timing Matters
2026-09-28
WM-8014 is a potent KAT6A inhibitor that can help researchers test whether KAT6-family acetyltransferase activity contributes to resistance-associated cell states. This article connects its pharmacology to time-gated CRISPR screening while separating useful assay hypotheses from conclusions the current evidence cannot support.
728 records 6/49 page Previous Next First page 上5页 678910 下5页 Last page